{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T06:05:05Z","timestamp":1780553105046,"version":"3.54.1"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The optimal combination therapy for carbapenem-resistant\n                      <jats:italic>Acinetobacter baumannii<\/jats:italic>\n                      (CRAB) pneumonia remains controversial. This study aimed to compare the microbiological efficacy, clinical outcomes, and safety of colistin-sulbactam versus colistin-tigecycline regimens in patients with CRAB hospital-acquired or ventilator-associated pneumonia (HAP\/VAP).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A single-center, retrospective cohort study was conducted from 2019 to 2024. Adult patients with culture-confirmed CRAB HAP\/VAP receiving either colistin-sulbactam (Group A) or colistin-tigecycline (Group B) for \u226572 hours were included. Propensity score matching (PSM) was utilized to balance baseline covariates, including APACHE II scores and renal function. The primary endpoint was microbiological eradication at Day 7; secondary endpoints included 28-day all-cause mortality, clinical cure, and adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 176 eligible patients, 42 matched pairs (n=84) were generated. The colistin-sulbactam group achieved significantly higher microbiological eradication rates at Day 7 compared to the colistin-tigecycline group (66.7% vs. 40.5%; P\u00a0=\u00a00.013). Subgroup analysis revealed that this benefit was particularly pronounced in patients with extensively drug-resistant (XDR) strains (OR 4.75; 95% CI 1.58\u201314.26) and those with multisite colonization. Clinical cure rates were also higher in Group A (59.5% vs. 35.7%; P\u00a0=\u00a00.029). No significant difference was observed in 28-day all-cause mortality (31.0% vs. 38.1%; P\u00a0=\u00a00.490).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Colistin combined with high-dose sulbactam demonstrated higher microbiological clearance and clinical cure rates compared to colistin-tigecycline, particularly in patients with XDR strains and high bacterial burden. The sulbactam-based regimen offers a favorable efficacy and safety profile and should be considered a preferred therapeutic strategy for severe CRAB infections.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcimb.2026.1804539","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:40:50Z","timestamp":1780551650000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of multisite colonization and comparative microbiological outcomes of colistin-sulbactam vs. colistin-tigecycline in CRAB hospital-acquired pneumonia: a propensity score-matched analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Shiyu","family":"Liao","sequence":"first","affiliation":[{"name":"Department of Respiratory, Yueyang Municipal Hospital of Hunan Normal University","place":["Yueyang, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Yueyang Municipal Hospital of Hunan Normal University","place":["Yueyang, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlae203","article-title":"Pharmacokinetic\/pharmacodynamic analysis of sulbactam against Acinetobacter baumannii pneumonia: establishing in vivo efficacy targets in the epithelial lining fluid","volume":"6","author":"Abouelhassan","year":"2024","journal-title":"JAC-Antimicrob. Resist."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlaf134","article-title":"The global epidemiology of carbapenem-resistant Acinetobacter baumannii","volume":"7","author":"Boutzoukas","year":"2025","journal-title":"JAC-Antimicrob. Resist."},{"key":"B3","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/INF.0000000000004582","article-title":"Therapeutic drug monitoring of high-dose sulbactam in pediatric patients: Preliminary data from a prospective observational pharmacokinetic study","volume":"44","author":"Charoenwong","year":"2025","journal-title":"Pediatr. Infect. Dis. J."},{"key":"B5","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3947\/ic.2024.0055","article-title":"Optimizing treatment for carbapenem-resistant Acinetobacter baumannii complex infections: A review of current evidence","volume":"56","author":"Choi","year":"2024","journal-title":"Infect. Chemother."},{"key":"B6","article-title":"Performance Standards for Antimicrobial Susceptibility Testing","volume-title":"33rd ed. CLSI supplement M100","year":"2023"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlad096","article-title":"Risk factors for carbapenem-resistant Acinetobacter baumannii (CRAB) bloodstream infections and related mortality in critically ill patients with CRAB colonization","volume":"5","author":"Cogliati Dezza","year":"2023","journal-title":"JAC-Antimicrob. Resist."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlaf262","article-title":"Risk factors for carbapenem-resistant Acinetobacter baumannii (CRAB) infections in critically ill patients with previous CRAB colonization: a multicentre cohort study","volume":"8","author":"Cogliati Dezza","year":"2026","journal-title":"JAC-Antimicrob. Resist."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106487","article-title":"Intrapulmonary pharmacokinetics of high doses of tigecycline in patients with ventilator-associated pneumonia","volume":"59","author":"Dimopoulos","year":"2022","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B10","volume-title":"Tygacil (tigecycline) for injection: US prescribing information","year":"2005"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics13111001","article-title":"Monitoring immune dysfunction in critically ill patients with carbapenem-resistant Acinetobacter baumannii sepsis treated with regimens including cefiderocol: A pilot study to identify accessible biomarkers to stratify patients' prognosis","volume":"13","author":"Frattari","year":"2024","journal-title":"Antibiotics (Basel)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.107047","article-title":"Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: A systematic review with meta-analysis","volume":"63","author":"Gatti","year":"2024","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-022-00369-z","article-title":"Coagulation dysfunction events associated with tigecycline: a real-world study from FDA adverse event reporting system (FAERS) database","volume":"20","author":"Guo","year":"2022","journal-title":"Thromb. J."},{"key":"B14","doi-asserted-by":"publisher","first-page":"92","DOI":"10.12688\/f1000research.129080.2","article-title":"Hospital-acquired and ventilator-associated pneumonia caused by multidrug-resistant Gram-negative pathogens: Understanding epidemiology, resistance patterns, and implications with COVID-19","volume":"12","author":"Hammoudi Halat","year":"2024","journal-title":"F1000Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00754","article-title":"Comparative metabolomics reveals key pathways associated with the synergistic killing of colistin and sulbactam combination against multidrug-resistant Acinetobacter baumannii","volume":"10","author":"Han","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics13090907","article-title":"Comparing the outcomes of cefoperazone\/sulbactam-based and non-cefoperazone\/sulbactam-based therapeutic regimens in patients with multiresistant Acinetobacter baumannii infections-a meta-analysis","volume":"13","author":"Huang","year":"2024","journal-title":"Antibiotics (Basel)"},{"key":"B17","unstructured":"IDSA guidance on the treatment of antimicrobial resistant gram-negative infections: version 4.0\n          \n          2024"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C\u2013based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","article-title":"Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)","volume":"23","author":"Kaye","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41100-018-0177-4","article-title":"KDIGO clinical practice guideline for acute kidney injury","volume":"2","year":"2012","journal-title":"Kidney Int. Suppl."},{"key":"B22","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1097\/00003246-198304000-00016","article-title":"APACHE II: a severity of disease classification system","volume":"13","author":"Knaus","year":"1985","journal-title":"Crit. Care Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1093\/cid\/ciu847","article-title":"Surveillance cultures growing carbapenem-resistant Acinetobacter baumannii predict the development of clinical infection: A retrospective cohort study","volume":"60","author":"Latibeaudiere","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"B25","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4103\/jrpp.jrpp_50_24","article-title":"Carbapenem-resistant Acinetobacter baumannii and ventilator-associated pneumonia; epidemiology, risk factors, and current therapeutic approaches","volume":"13","author":"Najafabadi","year":"2024","journal-title":"J. Res. Pharm. Pract."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1007\/s10096-024-04936-2","article-title":"Risk factors for infection after carbapenem-resistant Acinetobacter baumannii colonization","volume":"43","author":"Peghin","year":"2024","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2147\/IDR.S431525","article-title":"Treatment and management of Acinetobacter pneumonia: Lessons learned from recent world event","volume":"17","author":"Rangel","year":"2024","journal-title":"Infect. Drug Resist."},{"key":"B28","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3947\/ic.2021.0007","article-title":"Colistin plus sulbactam or fosfomycin against carbapenem-resistant Acinetobacter baumannii: Improved efficacy or decreased risk of nephrotoxicity","volume":"53","author":"Saelim","year":"2021","journal-title":"Pediatr. Infect. Dis. J."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics13060506","article-title":"Antibiotic treatment of carbapenem-resistant Acinetobacter baumannii infections in view of the newly developed \u03b2-lactams: A narrative review of the existing evidence","volume":"13","author":"Serapide","year":"2024","journal-title":"Antibiotics (Basel)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1053968","article-title":"Deciphering the virulence factors, regulation, and immune response to Acinetobacter baumannii infection","volume":"13","author":"Shadan","year":"2023","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciad428","article-title":"Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant Gram-negative infections","volume":"77","author":"Tamma","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/phar.2209","article-title":"International consensus guidelines for the optimal use of the polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2024.107267","article-title":"Effect of colistin combined with sulbactam: 9 g versus 12 g per day on mortality in the treatment of carbapenems resistant Acinetobacter baumannii pneumonia: A randomized controlled trial","volume":"149","author":"Ungthammakhun","year":"2024","journal-title":"Int. J. Infect. Dis."},{"key":"B34","unstructured":"Tygacil (tigecycline) for injection. Package insert\n          \n          2010"},{"key":"B35","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/BF01709751","article-title":"The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine","volume":"22","author":"Vincent","year":"1996","journal-title":"Intensive Care Med."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10091081","article-title":"Efficacies of colistin-carbapenem versus colistin-tigecycline in critically ill patients with CR-GNB-associated pneumonia: A multicenter observational study","volume":"10","author":"Wang","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2024.1395260","article-title":"Treatment of infections caused by carbapenem-resistant Acinetobacter baumannii","volume":"14","author":"Zhang","year":"2024","journal-title":"Front. Cell. Infect. Microbiol."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1804539\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:40:53Z","timestamp":1780551653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1804539\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":37,"alternative-id":["10.3389\/fcimb.2026.1804539"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2026.1804539","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"article-number":"1804539"}}